Home › Companies › CUE

Cue Biopharma, Inc.

CUE Lead: Preclinical 1 Biotech Distilled article ↓

Protein

Most recent annual filing: 2026-03-16

Pipeline (4 active programs)

CUE-401

Protein Target: TGF-β, IL-2

Undisclosed indication Preclinical

CUE-501

Protein Target: B cells

Undisclosed indication Preclinical Boehringer Ingelheim International GmbH

CUE-101

Protein Target: HPV

Undisclosed indication ImmunoScape Pte. Ltd.

CUE-102

Protein Target: WT1

Undisclosed indication ImmunoScape Pte. Ltd.

Technology platforms

Immuno-STAT

Modular biologics platform designed to selectively engage and modulate disease-specific T cells for autoimmune, inflammatory, and oncology indications. Enables selective Treg induction/expansion, targeted cell depletion via anti-viral T cell redirection, and tumor-specific T cell activation.

Targets: TGF-β, IL-2, T cells, Tregs

Biotech Distilled coverage (1)

2026-05-20 Cue Biopharma, Inc. (CUE) — Scientific Deep Dive for CUE-221 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.